Company Description
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.
It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands.
In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products.
Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum.
It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
| Country | United States |
| Founded | 2004 |
| IPO Date | Sep 18, 2015 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 4,700 |
| CEO | Adam Elsesser |
Contact Details
Address: One Penumbra Place Alameda, California 94502 United States | |
| Phone | 510 748 3200 |
| Website | penumbrainc.com |
Stock Details
| Ticker Symbol | PEN |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001321732 |
| CUSIP Number | 70975L107 |
| ISIN Number | US70975L1070 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Adam Elsesser J.D. | Co-Founder, Chairman and Chief Executive Officer |
| Ben Sorci | Executive Vice President of Operations |
| Pankaj Tiwari | Executive Vice President and Chief Information Officer |
| Jee Hamlyn-Harris | Investor Relations Officer |
| Ben Tompkins | Executive Vice President of Development and Compliance |
| Jason Richard Mills | Executive Vice President of Strategy |
| Dr. James F. Benenati FSIR, M.D. | Chief Medical Officer |
| Holly Sit | Director of Research and Development |
| Steve Chen | Director of Product Management |
| Cecilia E. Furlong | Director of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2026 | 10-Q | Quarterly Report |
| May 6, 2026 | 8-K | Current Report |
| Apr 30, 2026 | SCHEDULE 13G | Filing |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 23, 2026 | 425 | Filing |
| Apr 22, 2026 | 425 | Filing |
| Apr 17, 2026 | 425 | Filing |
| Apr 2, 2026 | 144 | Filing |